Netscientific Share Discussion Threads

[loafofbread] 08/6/2021 08:21

If you are thinking of holding for more than 5 minutes mm games shouldn't be an issue.

We were expecting the Glycotest news to take us up, not some left field event.

Yesterdays news will turbo charge ProAxis to a minimum £50M valuation.

PDSB will be $1B+ company so that's another £50M.

Glycotest is in the books at £10M. Trial results and news expected to turbo charge that.

Plus the rest of the portfolio.

[kalkaar] 08/6/2021 08:11

if you're thinking of getting in be careful - serious lack of liquidity - pullbacks will be fierce as witnessed at the bell..

[manual dexterity] 08/6/2021 08:08

2 pound plus.

[kalkaar] 08/6/2021 08:06

wow that's some drop lol

not sure anyone going to be running for the hills this time

buy the dips will be the order of the day i reckon..

[chesty1] 08/6/2021 08:04

Rinse n repeat watch this move during the day

[blakieboy7] 08/6/2021 08:01

Make that 165!

[fillipe] 08/6/2021 08:00

160p ask.

f

[loafofbread] 08/6/2021 07:55

To add to the above.

There is not enough vaccine to go round, even though AZ are at the forefront of production.

The need for booster vaccines/varient means that that supply will always be behind the curve.

Will this test go along side the multi million AZ vaccine to tell you when you need the booster jab.

Once your anti body levels drop to certain level you get the booster.

ProAxis still valued at zero, if you take away PDSB and Glycotest.

[the stigologist] 08/6/2021 00:24

NSCI

Nice overnight press follow up in The Times



NetScientific passes test for AstraZeneca licensing deal

An Aim-quoted life sciences company has struck an exclusive licensing agreement with AstraZeneca to sell a Covid-19 test.

Shares in NetScientific almost doubled after it said that its ProAxsis subsidiary would take responsibility for completing the validation and global commercialisation of the “finger-stick” blood test, which has been developed by an internal research team at AstraZeneca.

Ilian Iliev, chief executive of NetScientific and its largest shareholder, said that if “fully validated” the test could “attract a substantial market”.

NetScientific was listed on Aim, London’s junior stock market, in 2013, when it raised £30 million placing new shares at 160p each, but it is emerging from a period of upheaval and change. Its investors included the failed investment firm of Neil Woodford.

[loafofbread] 07/6/2021 23:34

If anyone doesn't know, ProAxis all ready has Neatstik products on the market at £25 a test.

See our NEATstik® Neutrophil Elastase Airways Test leaflet for full details

NEATstik® is a rapid point-of-care test, which allows the monitoring of active neutrophil elastase levels in sputum samples.

NEATstik® is usually supplied in boxes of 10 tests. If required, a single test can be provided at a cost of £28 plus shipping and VAT (if applicable) Box of 10 is £250

If you’d like further details on NEATstik®, please contact us via [e-mail]

The research team at AstraZeneca have already completed significant optimisation and validation work, which has demonstrated the assay's high potential sensitivity and specificity of detecting SARS-CoV-2 antibodies.

The development of this serology ELISA by our team is another example of AstraZeneca's comprehensive response to the COVID-19 pandemic. This highly sensitive and specific blood test makes use of simple and convenient fingerstick sample collection that will be well suited to large scale deployment and has the potential to play an important role in antibody analyses in large populations."

ProAxsis will take responsibility for completing the validation and global commercialisation of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA (enzyme-linked immunosorbent assay) developed by an internal research team at AstraZeneca. In return for providing access to the required intellectual property and technical know-how, AstraZeneca will receive an undisclosed royalty fee on future Global net sales of the assay.

AZ have all ready done 90% of the work and ProAxis have the test IP ready to go.

World wide product at a potential £25 a test, ready in a matter of weeks.

I might have to upgrade my £15 a share target.

[peaky00] 07/6/2021 22:50

NSCI is the new NYCT of 2021

[the stigologist] 07/6/2021 22:04

NSCI

Great breakaway gap candle today

Expect we take out year high tomorrow which is intraday circa 180p

Also hope we set a new 52 week closing high

NAV is north of 230p as things stand

Imminent Glycotest news could send us to 500p+ IMO

[everready1] 07/6/2021 22:01

Just seen your post you beat me to it

[investordave] 07/6/2021 22:01

Thanks kalkaar for those comforting words. I may have to up my entry target for more shares if I'm to increase my holding.

[everready1] 07/6/2021 22:00

Psdb up 11% in after hours trading to $10.43 so far

[kalkaar] 07/6/2021 21:56

I wouldn't bet on a sizeable pullback based on PDSB:

Data misinterpreted by Twitter and caused mini crash.. data was actually excellent and ahead of nearest competitor by a country mile for ORR and duration.

Recovered 11% in after hours.

PDSB conference call tmrw should confirm this.

Value in NSCI will be driven by AZN deal short term imho

[investordave] 07/6/2021 21:39

Hopefully that'll be the case but it would be surprising if the sharp pull back in PDSB's share price didn't have some impact on NSCI's performance tomorrow. I'll be in for few more in the morning if I can get in under 150p.

[bertiebingo] 07/6/2021 21:39

Non-PDSB is now 39% of NSCI mkt cap. Chances are NSCI corrects. My guess is 20-30% correction tomorrow assuming no move in PDSB then PDSB becomes 49-56% of mkt cap.

[bmwman3] 07/6/2021 21:24

Natural pullback Dave NSCI unaffected

[kalkaar] 07/6/2021 21:16

All Focus back on NSCI..

no numbers released yet on the potential AZN agreement with Proaxsis so speculation will be rife as to what this could be worth..

[kalkaar] 07/6/2021 21:10

Fwiw:

@avidresearch

$PDSB (post ASCO take): had the only really meaningful clinical update in HPV cancers this ASCO and they clearly are showing durable responses (80% responses ongoing in 8 months). Both ORR and duration of responses far exceed historical data in PD1 naive & R/R group.

[kalkaar] 07/6/2021 20:57

Updated data on bigger number set Have brought overall numbers down.. but still very good progress albeit less than reported back end of May..

Yanks selling the news..

PDSB has risen massively in the last month.. a good pullback should release a lot of hot air before carrying on the uptrend imho

[bertiebingo] 07/6/2021 20:53

ASCO can't be going well

[investordave] 07/6/2021 20:44

What the hell has happened at PDSB?

[everready1] 07/6/2021 17:36

I agree.Was frustrated and annoyed when I too tried to buy Arb around 50p! Now you can buy when no I don't want them!